Valneva SE (NASDAQ:VALN) Sees Significant Drop in Short Interest

Valneva SE (NASDAQ:VALN) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 15,900 shares, a decrease of 34.6% from the December 31st total of 24,300 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 38,300 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC lifted its holdings in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 118,000 shares of the company’s stock after purchasing an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 as of its most recent filing with the Securities and Exchange Commission. 11.39% of the stock is currently owned by institutional investors.

Valneva Price Performance

Shares of VALN opened at $4.95 on Wednesday. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The stock has a fifty day simple moving average of $4.30 and a two-hundred day simple moving average of $5.72. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70.

Analyst Ratings Changes

Separately, HC Wainwright reduced their price objective on Valneva from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.